Catalyst Pharmaceuticals, Inc. (CPRX)
NEUTRALFundamental
72
Price
$-
Market Cap
$3.85B
Part 1 · What the company is worth
Overview
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$597M
Trailing 12 months (through 3/31/2026)
Net Income
$221M
Trailing 12 months (through 3/31/2026)
Free Cash Flow
$172M
Total Equity
$1.01B
Total Liabilities
$3M
Current Ratio
7.10
Interest Coverage
-
Debt/EBITDA
0.01
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$47.09
Current Price
-
Margin of Safety
-
Fair Value Range
$30.61 - $63.58
Estimation Methods
Valuation Metrics
P/E Ratio
17.42
ROE
24.5%
P/B Ratio
3.80
P/FCF
-
Gross Margin
86.0%
ROIC
20.8%
Profitability Radar
Value Creation (Economic Moat)
ROIC
20.8%
WACC
8.0%
ROIC − WACC
+12.8 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (16)
- ROIC 20.8%
- Gross Margin 86.0%
- Debt/Equity ratio
- Operating Margin 44.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 23.6%
- Revenue Growth 5Y 37.7%
- Earnings Surprise avg 13.8%
- PEG Ratio 0.92
- Earnings Quality (OCF/NI) 0.94
- Net Margin Trend 37.1% vs 36.9%
Failed (4)
- P/B Ratio 3.80
- DCF valuation (Unknown)
- Analyst Consensus 0% Buy
- Piotroski F-Score 1/9
Unavailable (7)
- EPS data insufficient
- Historical price data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- Interest Coverage
- Price below Graham Number
- Share Dilution (missing shares data)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Moderate: some gap between profits and cash
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Patrick J. McEnany | Co-Founder & Non-Executive Chairman | 78 |
| Mr. Richard John Daly M.B.A. | President, CEO & Director | 64 |
| Mr. Michael W. Kalb CPA | Executive VP, Treasurer & CFO | 54 |
| Dr. Steven R. Miller Ph.D. | Executive VP, COO & Chief Scientific Officer | 63 |
| Mr. Jeffrey Del Carmen | Executive VP & Chief Commercial Officer | 54 |
| Dr. William T. Andrews FACP, M.D. | Chief Medical Officer | 60 |
| Ms. Mary Coleman | VP & Head of Investor Relations | - |
| Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer | 61 |
| Mr. Gregg Russo | Chief Human Resources Officer | 62 |
| Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer | 49 |
Audit Risk
8
Board Risk
3
Compensation Risk
8
Shareholder Rights Risk
4
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for CPRX, sourced from Markets Gazette.
- 4/27/2026POSITIVEItaly’s Angelini Said to Explore Acquisition of Catalyst Pharma
Catalyst Pharmaceuticals Inc. is reportedly being explored for acquisition by Italian drugmaker Angelini Pharma. This potential deal signals significant interest in Catalyst's assets and market position, suggesting a possible premium valuation for shareholders. Angelini Pharma's exploration indicates a strategic move to expand its global reach, potentially through acquiring Catalyst's product pipeline or market access. Investors will be watching for further developments, as an acquisition could lead to a substantial uplift in Catalyst's stock price.
- 4/27/2026NEUTRALItaly’s Angelini Said to Explore Catalyst Pharma Acquisition
Angelini Pharma, an Italian drugmaker, is reportedly exploring the acquisition of US-based Catalyst Pharmaceuticals Inc. This potential deal is part of Angelini's strategy to broaden its international presence. Catalyst Pharmaceuticals, trading on the Nasdaq, specializes in treatments for rare autoimmune diseases. While the exploration is in its early stages and no deal is guaranteed, the news highlights potential consolidation within the pharmaceutical sector. Investors will monitor developments for any concrete offers and the strategic rationale behind such a move.
via Markets Gazette